HK1124624A1 - Antibody binding p-selectin glycoprotein ligand 1 (psgl-1) for use in treating allergic disease - Google Patents

Antibody binding p-selectin glycoprotein ligand 1 (psgl-1) for use in treating allergic disease

Info

Publication number
HK1124624A1
HK1124624A1 HK09103684.6A HK09103684A HK1124624A1 HK 1124624 A1 HK1124624 A1 HK 1124624A1 HK 09103684 A HK09103684 A HK 09103684A HK 1124624 A1 HK1124624 A1 HK 1124624A1
Authority
HK
Hong Kong
Prior art keywords
cell
psgl
selectin glycoprotein
antibody binding
allergic disease
Prior art date
Application number
HK09103684.6A
Other languages
English (en)
Inventor
Lin Rong-Hwa
Wu Chung-Hsiun
Hsu Pei-Ling
Original Assignee
Abgenomics Cooeperatief U A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abgenomics Cooeperatief U A filed Critical Abgenomics Cooeperatief U A
Publication of HK1124624A1 publication Critical patent/HK1124624A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
HK09103684.6A 2001-08-03 2009-04-22 Antibody binding p-selectin glycoprotein ligand 1 (psgl-1) for use in treating allergic disease HK1124624A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31019601P 2001-08-03 2001-08-03
US10/051,497 US7744888B2 (en) 2001-08-03 2002-01-18 Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies

Publications (1)

Publication Number Publication Date
HK1124624A1 true HK1124624A1 (en) 2009-07-17

Family

ID=26729479

Family Applications (2)

Application Number Title Priority Date Filing Date
HK04108412.9A HK1065489A1 (en) 2001-08-03 2004-10-27 Modulators of p-selectin glycoprotein ligand 1
HK09103684.6A HK1124624A1 (en) 2001-08-03 2009-04-22 Antibody binding p-selectin glycoprotein ligand 1 (psgl-1) for use in treating allergic disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK04108412.9A HK1065489A1 (en) 2001-08-03 2004-10-27 Modulators of p-selectin glycoprotein ligand 1

Country Status (20)

Country Link
US (3) US7744888B2 (xx)
EP (2) EP1411982B1 (xx)
JP (3) JP4815101B2 (xx)
KR (1) KR100850731B1 (xx)
CN (2) CN1304051C (xx)
AT (2) ATE531734T1 (xx)
AU (1) AU2002305041B2 (xx)
CA (1) CA2428822C (xx)
CY (2) CY1108701T1 (xx)
DE (1) DE60229394D1 (xx)
DK (2) DK1985634T3 (xx)
ES (2) ES2376948T3 (xx)
HK (2) HK1065489A1 (xx)
IL (4) IL160168A0 (xx)
MX (1) MXPA04001047A (xx)
NO (2) NO333456B1 (xx)
NZ (1) NZ531199A (xx)
PT (2) PT1411982E (xx)
TW (1) TWI327070B (xx)
WO (1) WO2003013603A1 (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) * 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
NZ546203A (en) * 2003-09-15 2009-05-31 Abgenomics Co Modulators of P-Selectin Glycoprotein ligand 1
US7459523B2 (en) * 2003-11-12 2008-12-02 Wisconsin Alumni Research Foundation Equine P-selectin glycoprotein ligand-1 and uses thereof
UY28886A1 (es) * 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
AU2012201999C1 (en) * 2004-05-10 2016-05-12 Abgenomics Cooperatief U.A. Antibodies
NZ590478A (en) * 2004-05-11 2012-07-27 Abgenomics Cooperatief Ua Peptide motif Pro-Met-(Glu or Ser)-Ile used to identify a ligand which on binding an activated T-cell receptor induces apoptosis or cell death
WO2007033959A2 (en) * 2005-09-19 2007-03-29 Vib Vzw Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas
WO2007067984A2 (en) * 2005-12-09 2007-06-14 Wyeth Neutralizing antibodies against primate psgl-1 and uses therefor
JP2011524858A (ja) * 2008-05-15 2011-09-08 セレクシーズ ファーマスーティカルズ コーポレーション 抗psgl−1抗体並びにその同定及び使用方法
ES2387156B1 (es) * 2010-12-01 2013-07-04 Universidad Autónoma de Madrid Uso de psgl-1 para el tratamiento de enfermedades inflamatorias y autoinmunes
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
JP7240808B2 (ja) * 2014-07-08 2023-03-16 サンフォード バーナム プレビーズ メディカル ディスカバリー インスティテュート Psgl-1モジュレーターおよびその使用
TWI753875B (zh) 2016-01-08 2022-02-01 美商美國全心醫藥生技股份有限公司 四價抗psgl-1抗體及其用途
US20170241415A1 (en) * 2016-02-19 2017-08-24 Muzan, Inc. Sanitary check valve
KR20230132603A (ko) 2017-01-11 2023-09-15 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
CN110740749A (zh) 2017-03-14 2020-01-31 戊瑞治疗有限公司 在酸性pH下与VISTA结合的抗体
SG11202100102VA (en) 2018-07-11 2021-02-25 Five Prime Therapeutics Inc Antibodies binding to vista at acidic ph
BR112021000934A2 (pt) 2018-07-20 2021-04-27 Pierre Fabre Medicament receptor para vista
US20220221444A1 (en) * 2019-05-03 2022-07-14 The University Of Hong Kong Method for peritoneal metastatic cell detection and isolation thereof
BR112021024242A2 (pt) * 2019-06-04 2022-04-26 Verseau Therapeutics Inc Composições e métodos anti-psgl-1 para modular fenótipos inflamatórios de células mieloides e usos dos mesmos

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5378464A (en) * 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5464778A (en) * 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6309639B1 (en) * 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US5972625A (en) * 1991-05-06 1999-10-26 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US5710123A (en) * 1992-12-18 1998-01-20 Centocor, Inc. Peptide inhibitors of selectin binding
AU694933B2 (en) * 1993-01-25 1998-08-06 Dana-Farber Cancer Institute, Inc. Chimeric L- and P-selectin by exchange of domains - uses thereof
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
US5686426A (en) 1994-11-17 1997-11-11 Bristol-Myers Squibb Company Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
JPH11510543A (ja) 1995-08-03 1999-09-14 ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ オクラホマ ペプチド及びセレクチン介在炎症のo−グリカン阻害剤
JPH09227410A (ja) 1996-02-21 1997-09-02 Sumitomo Pharmaceut Co Ltd 臓器移植拒絶反応の抑制剤
WO1999043353A2 (en) * 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
IL142717A0 (en) 1998-10-30 2002-03-10 Genetics Inst Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
HUP0700079A2 (en) 2000-12-29 2007-05-02 Savient Pharmaceuticals Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US7744888B2 (en) * 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US20050152906A1 (en) * 2003-06-30 2005-07-14 Avigdor Levanon Specific human antibodies
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
NZ590478A (en) 2004-05-11 2012-07-27 Abgenomics Cooperatief Ua Peptide motif Pro-Met-(Glu or Ser)-Ile used to identify a ligand which on binding an activated T-cell receptor induces apoptosis or cell death
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF

Also Published As

Publication number Publication date
EP1985634A1 (en) 2008-10-29
AU2002305041B2 (en) 2005-11-10
IL160168A0 (en) 2004-07-25
CN101045161B (zh) 2010-06-16
ATE531734T1 (de) 2011-11-15
JP2008260759A (ja) 2008-10-30
NZ531199A (en) 2004-11-26
CN1304051C (zh) 2007-03-14
ES2316569T3 (es) 2009-04-16
US7744888B2 (en) 2010-06-29
CY1112966T1 (el) 2016-04-13
US8298540B2 (en) 2012-10-30
NO333456B1 (no) 2013-06-10
ATE411045T1 (de) 2008-10-15
DE60229394D1 (en) 2008-11-27
DK1411982T3 (da) 2009-02-16
CN1473052A (zh) 2004-02-04
CN101045161A (zh) 2007-10-03
NO20040460L (no) 2004-02-24
NO20130069L (no) 2004-02-24
IL210557A0 (en) 2011-03-31
CY1108701T1 (el) 2014-04-09
MXPA04001047A (es) 2005-02-17
JP2012092144A (ja) 2012-05-17
US8557579B2 (en) 2013-10-15
CA2428822A1 (en) 2003-02-20
PT1985634E (pt) 2012-02-07
HK1065489A1 (en) 2005-02-25
US20030049252A1 (en) 2003-03-13
JP4815101B2 (ja) 2011-11-16
IL204030A (en) 2014-11-30
WO2003013603A8 (en) 2004-06-10
WO2003013603A1 (en) 2003-02-20
EP1411982B1 (en) 2008-10-15
IL204030A0 (en) 2011-08-01
IL160168A (en) 2011-02-28
NO334850B1 (no) 2014-06-16
KR100850731B1 (ko) 2008-08-06
CA2428822C (en) 2014-10-28
US20130011861A1 (en) 2013-01-10
JP2004521958A (ja) 2004-07-22
KR20040054670A (ko) 2004-06-25
EP1411982A4 (en) 2004-10-06
EP1985634B1 (en) 2011-11-02
EP1411982A1 (en) 2004-04-28
US20090304709A1 (en) 2009-12-10
TWI327070B (en) 2010-07-11
PT1411982E (pt) 2008-12-24
DK1985634T3 (da) 2012-02-20
ES2376948T3 (es) 2012-03-21

Similar Documents

Publication Publication Date Title
HK1124624A1 (en) Antibody binding p-selectin glycoprotein ligand 1 (psgl-1) for use in treating allergic disease
PT966485E (pt) Domínios de igg2 mutados não activantes e anticorpos anti-cd3 incorporando os mesmos
WO2005027831A3 (en) Modulators of p-selectin glycoprotein ligand 1
EP1461081A4 (en) ANTI-CD45RB ANTIBODY FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES AND TRANSPLANT ABLUSION
SG155205A1 (en) Interleukin-10 antibodies
IL201889A (en) Medication for the treatment of vaccine-related disorders containing antibodies that specifically recognize the nk 1.1 antigen or cd56 antigen expressed by nk t cells
EP1135415A4 (en) HUMANIZED ANTIBODIES AGAINST GAMMA INTERFERON
NO20060189L (no) Antistoffer mot interleukin-22 og anvendelse derav
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
HUP0100763A2 (hu) Humán CD 40 elleni antitestek
EP0765172A4 (en) FOR E-SELECTIN AND P-SELECTIN-SPECIFIC CROSS-REACTIVE MONOCLONAL ANTIBODIES
IL163851A (en) Internalizing anti-cd74 antibodies and methods of use
DE69316948D1 (de) Lösliche Liganden für CD40
PT1157042E (pt) Produção de anticorpos tetravalentes
IL169152A0 (en) Antibodies against pd-1 and uses therefor
DE60334453D1 (de) Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
NZ331418A (en) Iscom or iscom-matrix comprising hydrophobic receptor molecules for antigenic substances
GR3026219T3 (en) Mouse monoclonal antibodies
DE60234115D1 (de) Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier
WO2006033688A3 (en) Anti-lympho- plus anti-monocytes globulin preparation for inhibiting immune responses
PL325667A1 (en) Antibodies effective against fas
TW200513262A (en) Modulators of P-selectin glycoprotein ligand 1
Legny Under the auspices of: The International Association for Ecology (INTECOL), The International Union for Biological Sciences (IUBS) and The Polish Academy of Sciences. Major theme: Ecology as a Basis for Environmental Management and Human Welfare
Szlufcik et al. Modulation of inositol 1, 4, 5-trisphosphate receptor type 1 activity by thimerosal and calcium
ATA20080A (de) Verfahren und vorrichtung zum reinigen von klein- gegenstaenden, wie geschirr, glaeser, bestecke u.dgl., insbesondere aus thermolabilen werkstoffen

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180313